U.S. Markets close in 1 hr 18 mins
  • S&P 500

    4,704.54
    +15.87 (+0.34%)
     
  • Dow 30

    35,870.95
    -60.10 (-0.17%)
     
  • Nasdaq

    15,993.71
    +72.14 (+0.45%)
     
  • Russell 2000

    2,363.59
    -13.42 (-0.56%)
     
  • Gold

    1,861.20
    -0.20 (-0.01%)
     
  • Silver

    24.88
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1369
    -0.0006 (-0.0568%)
     
  • 10-Yr Bond

    1.5890
    -0.0150 (-0.94%)
     
  • Vix

    17.59
    +0.48 (+2.81%)
     
  • GBP/USD

    1.3497
    -0.0003 (-0.0216%)
     
  • USD/JPY

    114.3040
    +0.0520 (+0.0455%)
     
  • BTC-USD

    58,169.18
    +3,357.70 (+6.13%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • FTSE 100

    7,255.96
    -35.24 (-0.48%)
     
  • Nikkei 225

    29,683.09
    +84.43 (+0.29%)
     

Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Bristol Myers Squibb (BMY) closed the most recent trading day at $58.36, moving +1.14% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.75%.

Coming into today, shares of the biopharmaceutical company had lost 5.77% in the past month. In that same time, the Medical sector lost 4.31%, while the S&P 500 lost 0.05%.

BMY will be looking to display strength as it nears its next earnings release, which is expected to be October 27, 2021. In that report, analysts expect BMY to post earnings of $1.91 per share. This would mark year-over-year growth of 17.18%. Meanwhile, our latest consensus estimate is calling for revenue of $11.55 billion, up 9.59% from the prior-year quarter.

For the full year, our Zacks Consensus Estimates are projecting earnings of $7.47 per share and revenue of $46.32 billion, which would represent changes of +15.99% and +8.94%, respectively, from the prior year.

Any recent changes to analyst estimates for BMY should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.04% higher. BMY is holding a Zacks Rank of #3 (Hold) right now.

Looking at its valuation, BMY is holding a Forward P/E ratio of 7.72. For comparison, its industry has an average Forward P/E of 23.97, which means BMY is trading at a discount to the group.

Meanwhile, BMY's PEG ratio is currently 1.1. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. BMY's industry had an average PEG ratio of 1.53 as of yesterday's close.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 175, putting it in the bottom 32% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.